Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Retained Earnings: 2019-2025

Historic Retained Earnings for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $1.0 billion.

  • Legend Biotech's Retained Earnings fell 9.39% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 9.39%. This contributed to the annual value of $1.0 billion for FY2024, which is 16.81% down from last year.
  • As of Q3 2025, Legend Biotech's Retained Earnings stood at $1.0 billion, which was down 2.34% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Retained Earnings peaked at $1.4 billion during Q2 2023, and registered a low of $206,424 during Q1 2021.
  • Its 3-year average for Retained Earnings is $1.1 billion, with a median of $1.1 billion in 2024.
  • Per our database at Business Quant, Legend Biotech's Retained Earnings soared by 358,932.38% in 2022 and then fell by 17.63% in 2024.
  • Over the past 5 years, Legend Biotech's Retained Earnings (Quarterly) stood at $766.0 million in 2021, then dropped by 2.87% to $744.0 million in 2022, then surged by 68.19% to $1.3 billion in 2023, then fell by 16.81% to $1.0 billion in 2024, then dropped by 9.39% to $1.0 billion in 2025.
  • Its Retained Earnings was $1.0 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.